EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of Artemisia annua sublingual immunotherapy in patients with seasonal allergic rhinoconjunctivitis over two pollen seasons

Jiayi Yang, Weidong Wang, Zhen Shen, Wei Kang, Pengfei Zhang, Xin Chen, Huajing Li, Yuan Shao, Lifeng Liu, Shaoqiang Zhang, Fang Quan

European Archives of Oto-Rhino-Laryngology · 2023-11 · 280 (11) · 4939-4947

DOI: 10.1007/s00405-023-08078-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 26.06.2023. Verfasst von Jiayi Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology Head and Neck Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xian, 710061, China. Hauptthemen laut MEDLINE: Sublingual Immunotherapy, Rhinitis, Allergic, Seasonal, Artemisia annua, Conjunctivitis, Allergic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Key Research and Development Projects of Shaanxi Province, First Affiliated Hospital of Zhengzhou University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study investigates the efficacy and safety of sublingual immunotherapy (SLIT) with A. annua allergens in patients with seasonal allergic rhinoconjunctivitis over two pollen seasons. METHODS: Seventy patients with moderate-severe seasonal allergic rhinoconjunctivitis were divided evenly into the SLIT and control groups. The SLIT last from 3 months before the summer-autumn pollen season in 2021 till the end of the summer-autumn pollen season in 2022. The daily individual symptom score, total rhinoconjunctivitis symptom score (dTRSS), total medication score (dTMS), combined score of medication and rhinoconjunctivitis symptom (dCSMRS), visual analog scale (VAS) score, and adverse events (AEs) were evaluated. RESULTS: The average pollen concentration in 2022 was twice that previous two-year during the pollen season. Fifty-six patients completed treatments (SLIT group: 29, control group: 27). Compared with baseline, the individual symptoms, dTRSS, dTMS, dCSMRS, and VAS scores of SLIT group declined in 2021. After 16 months of SLIT, all efficacy indexes in 2022 were still lower than baseline and equivalent to those in 2021. In control group, the efficacy indexes in 2022 were higher than that in 2020 and 2021. The efficacy indexes of SLIT group were lower than those of control group in 2021 and 2022. SLIT is effective for both mono- and poly-sensitized patients. AEs incidence in SLIT group was 82.7% without severe AEs. CONCLUSIONS: The A. annua-SLIT can obtain efficacy and safety over two pollen seasons for patients with moderate-severe seasonal allergic rhinoconjunctivitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sublingual ImmunotherapyRhinitis, Allergic, SeasonalArtemisia annuaConjunctivitis, AllergicHumansSeasonsDouble-Blind MethodPollenAllergensDesensitization, ImmunologicTreatment Outcome

Stichwörter der Autor:innen

Allergic conjunctivitisAllergic rhinitisInhaled allergenPollen concentration

Substanzen

Allergens

Autor:innen und Institutionen

  • Department of Otolaryngology Head and Neck Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xian, 710061, China.
  • Department of Otolaryngology Head and Neck Surgery, NO. 215 Hospital of Shaanxi Nuclear Industry, Xianyang, 710054, China.
  • Department of Otolaryngology Head and Neck Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xian, 710061, China. entsqzhang@163.com.
  • Department of Otolaryngology Head and Neck Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xian, 710061, China. quanfang2013@163.com.

Förderung

  • Key Research and Development Projects of Shaanxi Province
  • First Affiliated Hospital of Zhengzhou University

Zitieren

APA

Yang, J., Wang, W., Shen, Z., Kang, W., Zhang, P., Chen, X., Li, H., Shao, Y., Liu, L., Zhang, S., & Quan, F. (2023). Efficacy and safety of Artemisia annua sublingual immunotherapy in patients with seasonal allergic rhinoconjunctivitis over two pollen seasons. European Archives of Oto-Rhino-Laryngology, 280(11), 4939-4947. https://doi.org/10.1007/s00405-023-08078-7

Vancouver

Yang J, Wang W, Shen Z, Kang W, Zhang P, Chen X, et al. Efficacy and safety of Artemisia annua sublingual immunotherapy in patients with seasonal allergic rhinoconjunctivitis over two pollen seasons. European Archives of Oto-Rhino-Laryngology. 2023;280(11):4939-4947. doi:10.1007/s00405-023-08078-7

BibTeX
@article{Yang2023,
  author = {Yang, Jiayi and Wang, Weidong and Shen, Zhen and Kang, Wei and Zhang, Pengfei and Chen, Xin and Li, Huajing and Shao, Yuan and Liu, Lifeng and Zhang, Shaoqiang and Quan, Fang},
  title = {Efficacy and safety of Artemisia annua sublingual immunotherapy in patients with seasonal allergic rhinoconjunctivitis over two pollen seasons},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2023},
  volume = {280},
  number = {11},
  pages = {4939--4947},
  doi = {10.1007/s00405-023-08078-7}
}
Kostenlos starten →